share_log

Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target

Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target

瑞基農表示,高劑量眼藥Eylea HD的三期臨床試驗達到了主要目標。
MT Newswires ·  08:01

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論